Aseptically Prepared Systemic Anti-Cancer Therapy Medicines
AwardHighlights
- Award value
- £2,550,000,000
- Winning supplier
- Baxter Healthcare Ltd, Quantum Pharmaceutical Limited
- Award date
- 26 Oct 2026
Details
- Published
- 26 Oct 2026
- Deadline
- —
- Value
- £2,550,000,000
- Location
- —
- Source
- Find a Tender
- Source notice ID
- 100972-2026
- OCID
- ocds-h6vhtk-051cde
- CPV codes
- —
Description
This framework agreement is for the supply of a range of aseptically prepared, batch manufactured systemic anti-cancer therapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific systemic anti-cancer therapy drugs and medicines used in CIVAs.
More from Mid South Essex NHS Foundation Trust
View all- Linen and Laundry Services Tender NoticeTenderMid South Essex NHS Foundation TrustCloses 2 Dec 2026
- Taxi Services Dynamic MarketTenderMid South Essex NHS Foundation TrustCloses 20 Aug 2030
Lots (4)
| Lot | Title | Value |
|---|---|---|
| 1 | Lot 1 | — |
| 2 | Lot 2 | — |
| 3 | Lot 3 | — |
| 4 | Lot 4 | — |
Awarded contracts (4)
| Title | Supplier | Value | Awarded |
|---|---|---|---|
| Dose Banded Systemic Anti-Cancer Therapy Medicines | Baxter Healthcare Ltd | £850,000,000 | 26 Oct 2026 |
| Patient Specific Systemic Anti-Cancer Therapy Medicines | Baxter Healthcare Ltd | £850,000,000 | 26 Oct 2026 |
| CIVAS (Central Intravenous Additive Service) | Quantum Pharmaceutical Limited | £850,000,000 | 26 Oct 2026 |
| Award -1 | — | — | — |